dem dry bones quick update for a busy gp
play

Dem Dry Bones - quick update for a busy GP Professor David Kane 1 - PowerPoint PPT Presentation

Dem Dry Bones - quick update for a busy GP Professor David Kane 1 Who to Screen? All women age 65 or older All men age 70 or older Fracture after age 50 Peri / postmenopausal woman < 65 with risk factors Men age 50-69


  1. Dem Dry Bones - quick update for a busy GP Professor David Kane 1

  2. Who to Screen? All women age 65 or older • All men age 70 or older • Fracture after age 50 • Peri / postmenopausal woman < 65 with risk factors • Men age 50-69 with risk factors • Individualising treatment: those who will most benefit from treatment balanced with risk of adverse events

  3. Osteoporosis Risk Factors Advancing age • Previous fracture • Glucocorticoid therapy …. Any dose for planned 3 months • Family history of hip fracture • Low body weight (BMI <19) • Neuromuscular disorders • Smoking • Alcohol >2 units/day • Medical - Rheumatoid arthritis, Inflammatory bowel disease, Coeliac • disease, Cystic fibrosis, Previous hyperthyroidism, Type 1 and 2 diabetes, Renal disease. Therapeutic - Androgen deprivation agents, aromatase inhibitors, proton • pump inhibitors, selective serotonin reuptake inhibitors (SSRIs) and anticonvulsants 4

  4. FRAX for screening 10y probability of major Patient osteoporotic fracture Age(years)

  5. AACE/ACE 2016 Guidelines for the Treatment of Postmenopausal Osteoporosis Osteopenia (T-score between -1.0 and -2.5) and a history of fragility fracture Osteopenia with a FRAX 10-year probability >3% for hip fracture or >20% for other major osteoporotic fracture T-score at any location <-2.5 Osteoporosis may also be diagnosed with a history of a low-trauma fracture, regardless of T-score

  6. How to Treat - Lifestyle Measures Stop smoking Exercise Weight-bearing exercises. • Muscle-strengthening exercises • Balance exercises and Flexibility exercises • Physical Activity Associated with lower total and Hip fracture

  7. How to Treat - Lifestyle Measures Calcium (1200mg) Calcium Intake 1200 mg/day Supermilk – 400mg Ca in 250mls, 200 IU Vit D • Orange Juice (with Calcium) 300mg in 250mls • Calcium Citrate (eg Solgar) if on PPI Cardiac Risk unproven Try to achieve by dietary means • Do not exceed 2000mg/day •

  8. How to Treat - Lifestyle Measures Vitamin D (800IU or 20mcg) When to test? When osteoporosis diagnosed but also in winter • Annually in patient on treatment for osteoporosis • Effect of supplementation takes several months • Sources UV light – 20-25 minutes of sun exposure – 21 yo – 10,000IU • Diet – Oily fish best source – 100g salmon portion = 500IU • Insufficiency 1000 IU daily (normal diet plus supplement) • Toxicity Very rare – hypercalcaemia and hypercalciuria •

  9. Antiresorptive treatment - Bisphosphonates First line treatment for postmenopausal women with osteoporosis Proven efficacy, low cost, availability of long-term safety data Alendronate or Risedronate – lack of hip efficacy in ibandronate Risedronate 150mg/month efficacious but not available as single tablet …………………. Delmas et al, Bone. 2008;42(1):36. Epub 2007 Sep 8. Optimal duration of treatment is not known At 5 years treatment check DEXA and assess risk Stop low risk patients and monitor DEXA 2 yearly • Continue high risk patients with denosumab for 5 years • If stopped, restart if femoral neck BMD reduces by 5%

  10. HORIZON Study Rates of Fracture and Death in the Study Groups. Lyles KW et al. N Engl J Med 2007;357:1799-1809.

  11. Anabolic Treatment Denosumab Parathormone 60mg sc 6 monthly • Teriparatide (EU) • Sustained 10 yr BMD gains • 20mcg sc daily (pen) • Need run off cover with • 2 year therapy • bisphosphonate (BP) GIOP - Superior to BP • GIOP - equivalent to BP • Abaloparatide not approved • Consider anabolic treatment in severe osteoporosis – post fragility fracture 13

  12. Romosuzumab • MAb that neutralises Sclerostin • Anabolic AND Antiresorptive • S.C. Monthly for one year • Then bisphosphonate • Superior to Alendronate in BMD gain • Superior to Alendronate in all # • Increased serious CVS events in placebo trial • Avoid in patients with MI/CVA within 1 year

  13. Incidence of New Vertebral, Clinical, and Nonvertebral Fracture. Saag KG et al. N Engl J Med 2017;377:1417-1427.

  14. Secondary Fracture Prevention Risk of a subsequent fracture at least doubled after a first fragility • fracture Treatment can reduce the risk of second fracture by 50% to 70% • Decline in treatment initiation in patients with hip fracture from • approximately 10% in 2004 to just over 3% in 2015 …. JAMA Netw Open 2018;1:e180826

  15. Management of Hip, Vertebral and Wrist Fracture Treat all over 65 hip and vertebral fractures • Diagnose at presentation with first fracture • Do not delay for DEXA or Fracture healing • Daily Vitamin D 800IU & Calcium 1200 mg • Initiate therapy immediately • Zoledronic acid reduces post hip fracture mortality •

  16. • Review of steroid claims USA • Range of awards $25 000 to $8.1 million. • Complications sued for often multiple • Avascular necrosis (39%) • Mood changes (16%) • Visual complaints (14%) • Osteoporosis (12%) • Infectious complications (14%)

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend